Clinical Trial

Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis

Completed
View on ClinicalTrials.gov →
Summary
Anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors (VEGF/TKI-ICI) plus Immune checkpoint inhibitors (ICIs) are recommended for patients with unresectable hepatocellular carcinoma (HCC) with PVTT in China. However, these treatments have limited survival benefit in patients with advanced HCC with PVTT. We aimed to investigate whether hepatic arterial infusion chemotherapy (HAIC) in combination with VEGF/TKI-ICI and ICIs could improve the efficacy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-12.
Status change: Recruiting → Completed 2026-05-07
Trial Details
NCT Number NCT06881433
Lead Sponsor Zhongda Hospital
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 1,649 participants
Start Date 2018-06-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-11